OGYÉI approves China's Sinopharm vaccine

Pharma

Image by Shutterstock.com

Hungary's National Institute of Pharmacy and Nutrition (OGYÉI) has approved a COVID-19 vaccine developed by China's Sinopharm, the country's chief medical officer said at a daily press briefing on Friday, according to a report by state news wire MTI.

Cecília Müller said Hungarians can now "count on" COVID-19 vaccines developed by BioNTech/Pfizer, Moderna, and AstraZeneca, as well as Russia's Sputnik V vaccine and now the Sinopharm vaccine.

Minister of Foreign Affairs and Trade Péter Szijjártó said in a post on Facebook later on Friday that Hungary would buy 5 million doses of the Sinopharm vaccine, enough to inoculate 2.5 million people.

Szijjártó said he had spoken by phone with his Chinese counterpart Wang Yi after attending a ceremony to inaugurate an LNG terminal in Croatia. A contract on acquiring the Sinopharm vaccine was signed in the morning, he added.

The deliveries of the vaccine will take place in four phases over four months, he said.

He noted that more than 300,000 people in neighboring Serbia had been inoculated with the Sinopharm vaccine.

 

ADVERTISEMENT

Companies Borrow HUF 256 bln in October Banking

Companies Borrow HUF 256 bln in October

MPs Approve Tax Changes Parliament

MPs Approve Tax Changes

Mahart Container Center Depot Opening at Budapest Airport Transport

Mahart Container Center Depot Opening at Budapest Airport

Countries Exchange Experiences for Better Production of Catt... Conferences

Countries Exchange Experiences for Better Production of Catt...

SUPPORT THE BUDAPEST BUSINESS JOURNAL

Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.